# Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)

> **NCT00684515** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 90 (actual)

## Conditions studied

- Cerebral Infarction

## Interventions

- **DRUG:** Vorapaxar 2.5 mg
- **DRUG:** Vorapaxar 1 mg
- **DRUG:** Placebo
- **DRUG:** Aspirin 75-150 mg

## Key facts

- **NCT ID:** NCT00684515
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09-21
- **Primary completion:** 2007-11-08
- **Final completion:** 2007-11-08
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2018-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00684515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00684515, "Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00684515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*